Remifentanil B Braun for Anesthesia induction and maintenance
Quick answer: Remifentanil B Braun is used for Anesthesia induction and maintenance as part of a opioid analgesic (ultra-short-acting) treatment regimen. Selective mu-opioid receptor agonist rapidly metabolized by nonspecific esterases (B. Braun branded generic) The specific dosing for Anesthesia induction and maintenance is determined by your prescriber based on individual factors.
Why is Remifentanil B Braun used for Anesthesia induction and maintenance?
Remifentanil B Braun belongs to the Opioid analgesic (ultra-short-acting) class. Selective mu-opioid receptor agonist rapidly metabolized by nonspecific esterases (B. Braun branded generic) This action makes it useful for treating or managing Anesthesia induction and maintenance in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Remifentanil B Braun is the right choice for a specific patient depends on the type and severity of Anesthesia induction and maintenance, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Anesthesia induction and maintenance
Common adult dosing range: 0.05-2 mcg/kg/min IV infusion. The actual dose for Anesthesia induction and maintenance depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Remifentanil B Braun medicine page.
What to expect
Remifentanil B Braun treatment for Anesthesia induction and maintenance typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Anesthesia induction and maintenance
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Remifentanil B Braun is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Opioid analgesic (ultra-short-acting) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Remifentanil B Braun
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Remifentanil B Braun full prescribing information · All Opioid analgesic (ultra-short-acting) alternatives
Frequently asked questions
How effective is Remifentanil B Braun for Anesthesia induction and maintenance?
Effectiveness varies by individual response, dose, and severity. Remifentanil B Braun is one of several treatment options for Anesthesia induction and maintenance, supported by clinical evidence within the opioid analgesic (ultra-short-acting) class. Discuss expected response with your prescriber.
How long do I need to take Remifentanil B Braun for Anesthesia induction and maintenance?
Treatment duration depends on the nature of Anesthesia induction and maintenance — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Remifentanil B Braun when used for Anesthesia induction and maintenance?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Remifentanil B Braun for Anesthesia induction and maintenance?
Yes. Multiple medicines and non-drug options exist for Anesthesia induction and maintenance. Alternatives within the opioid analgesic (ultra-short-acting) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.